Top segments and regional performance

Last year, the company generated ‪262.60 M‬ USD, the most of which — ‪262.60 M‬ USD — came from its top-performing segment, Protein Degradation Therapies, compared to ‪263.40 M‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪262.60 M‬ USD last year, with ‪263.40 M‬ USD the year before.